Journal
INFECTION AND CHEMOTHERAPY
Volume 54, Issue 1, Pages 189-194Publisher
KOREAN SOC ANTIMICROBIAL THERAPY
DOI: 10.3947/ic.2021.0131
Keywords
COVID-19 vaccine; Aseptic meningitis; BNT162b2 mRNA vaccine; Adverse reaction
Categories
Funding
- Jeju National University
Ask authors/readers for more resources
COVID-19 vaccines may lead to rare neurological adverse events, including aseptic meningitis. A 32-year-old man developed headaches after receiving the vaccine, and his symptoms improved with treatment.
Vaccines are one of the most important strategies against pandemics or epidemics involving infectious diseases. With the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there have been global efforts for rapid development of coronavirus disease 2019 (COVID-19) vaccine and vaccination is being performed globally on a massive scale. With rapid increase in vaccination, rare adverse events have been reported. Well-known neurological adverse events associated with COVID-19 vaccination include Guillain-Barre syndrome, myelitis, and encephalitis. However, COVID-19 vaccine-related aseptic meningitis has rarely been reported. A 32-year-old healthy man visited our hospital with a complaint of headache for 1 week. He had received the second dose of the BNT162b2 mRNA COVID-19 vaccine 2 weeks before the onset of headache. Since the initial cerebrospinal fluid (CSF) profile suggested viral meningitis, we started treatment with an antiviral agent. However, the symptoms and follow-up CSF profile on day 7 of hospitalization showed no improvement and SARS-CoV-2 IgG antibodies were detected in the CSF. We suspected aseptic meningitis associated with the vaccination and intravenous methylprednisolone (500 mg/day) was administered for 3 days. The symptoms improved and the patient was discharged on day 12 of hospitalization.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available